Status:
UNKNOWN
Lactoferrin Use in (SARS-CoV-2) Management
Lead Sponsor:
Zagazig University
Conditions:
Covid19
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Background: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), viral respiratory diseas...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- participants over 20 years of age
- positive for nasopharyngeal swab reverse transcriptase polymerase chain reaction (RT-PCR) for COVID-19
- blood oxygen saturation (SpO2) \> 93%.
- Exclusion criteria:
- pregnant and breastfeeding women
- individuals confirmed to be allergic to milk protein
- those with a medical history of bronchial hyperactivity or pre-existing respiratory diseases
- ICU inpatients with COVID-19.
Exclusion
Key Trial Info
Start Date :
July 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2021
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04860219
Start Date
July 8 2020
End Date
April 30 2021
Last Update
April 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine -Zagazig University
Zagazig, Egypt